Regulus Therapeutics Inc

Regulus Therapeutics — Technical Presentation (March 2025)

10 slides from Regulus Therapeutics's technical presentation, Mar 27, 2025

  1. Slide 1: Phase 1b Trial Cohort 4 Final Efficacy Results

    Phase 1b Trial Cohort 4 Final Efficacy Results. March 27, 2025 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus’ farabursen (RGLS8429) program, the potential that farab

  3. Slide 3: Study Design

    STUDY DESIGN ADPKD patients (Mayo Class 1C, 1D or 1E) 3-month dosing (Q2W x 7) Cohorts 1-3 Objectives Safety & tolerability Placebo-controlled, weight-based dose range evaluation of polycystin biomarker Exploratory evaluation of effect on total kidney volume Cohort 4 Objectives Open-label evaluation

  4. Slide 4: Baseline Characteristics Representative of Target Patient Population

    Baseline Characteristics Representative of Target Patient Population. Enrolled population represents significant disease burden by kidney size and reduced eGFR Similar enrollment criteria planned for pivotal Phase 3 trial Farabursen Baseline Characteristics Placebo N=10 1 mg/kg N=9 2 mg/kg N=11 3 mg

  5. Slide 5: Final Cohort 4 Data Show Maximal Mechanistic Activity with 300 mg Fixed Dose

    Geometric least squares mean percent change data shown. Error bars represent standard errors. ANCOVA analyses performed on log scale transformation to account for non-normal distribution. Data not available for one subject in each of 3 mg/kg and 300 mg/kg Fixed groups. Final Cohort 4 Data Continue t

  6. Slide 6: Final Cohort 4 Data Show Reduction in htTKV Growth Rate with 300 mg Fixed Dose

    Geometric least squares mean percent change data shown. Error bars represent standard errors. ANCOVA analyses performed on log scale transformation to account for non-normal distribution. EOS, End of study. Data not available for two subjects in 3 mg/kg group and one subject in 300 mg Fixed group. O

  7. Slide 7: Cohorts 3 & 4 Combined Demonstrate Halting of Disease Progression Over 4 Months

    Geometric least squares mean percent change data shown. Error bars represent standard errors. ANCOVA analyses performed on log scale transformation to account for non-normal distribution. EOS, End of study. Data not available for two subjects in 3 mg/kg group and one subject in 300 mg Fixed group. O

  8. Slide 8: Exploratory Testing Shows High Statistical Significance Versus Combined Historical Placebo

    p=0.00562 p=0.06947 Exploratory Testing Demonstrates High Statistical Significance Between Farabursen at the Target Exposure and Combined Historical Placebo Statistical testing: MMRM comparison of distributions. Hx PBO created using Bayesian augmentation with Hx PBO data treated as prior information

  9. Slide 9: Cohort 4 Final Efficacy Results Summary

    Increases in polycystin biomarkers consistent with top end of dose range 300 mg provided evidence of maximal mechanistic activity with no indication that higher doses will achieve greater levels of urinary polycystin Farabursen continues to show evidence of a notable effect on TKV growth rate 300 mg

  10. Slide 10: Regulus

    REGULUS

Regulus Therapeutics — Technical Presentation (March 2025) on 6ix